Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: Factors associated with liver toxicities

James E. Goin; Riad Salem; Brian I. Carr; Janet E. Dancey; Michael C. Soulen; Jean Francois H. Geschwind; Kathleen Goin; Mark Van Buskirk; Kenneth Thurston

doi:10.1097/01.RVI.00001142592.89564.F9

Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: Factors associated with liver toxicities

James E. Goin, Riad Salem^*, Brian I. Carr, Janet E. Dancey, Michael C. Soulen, Jean Francois H. Geschwind, Kathleen Goin, Mark Van Buskirk, Kenneth Thurston

^*Corresponding author for this work

Radiology

Research output: Contribution to journal › Article › peer-review

148 Scopus citations

Abstract

PURPOSE: Intraarterial injection of yttrium 90 microspheres (TheraSpheres) is used in the treatment of hepatocellular carcinoma (HCC). This article presents an analysis of the incidence of liver toxicities (liver-related events) and pretreatment factors associated with liver toxicities after TheraSphere treatment. PATIENTS AND METHODS: Eighty-eight TheraSphere-treated patients with low 90-day mortality risk were selected for analysis, with liver toxicities coded with use of standard oncology criteria. Descriptive and inferential statistical methods were applied to estimate the incidence of liver toxicities and to evaluate the influence of liver radiation dose and various pretreatment factors on the risk of their occurrence. RESULTS: Sixty-eight liver toxicities occurred in 37 of the 88 patients (42%). Thirty-two patients (36%) experienced 50 liver toxicities after the first treatment and nine of 23 patients (39%) who received a second treatment experienced 18 liver toxicities. Pretreatment total bilirubin and liver radiation dose were found to be associated with the risk of at least one liver toxicity and with the time to first occurrence of a liver toxicity after first treatment. Pretreatment total bilirubin also was associated with liver toxicities after the second treatment. Most of the toxicities resolved; however, those that did not resolve were attributed to tumor progression or advancing cirrhosis. CONCLUSIONS: The risk of liver toxicities in patients with unresectable HCC treated with TheraSpheres increases with increasing pretreatment total bilirubin level and liver radiation dose to a maximum of 150 Gy for a single administration. The toxicities attributed to treatment resolved over time, and none of the patients studied had confirmed radiation-induced liver disease. Consequently, doses as high as 150 Gy on a single administration and as high as 268 Gy on repeated administrations were well tolerated.

Original language	English (US)
Pages (from-to)	205-213
Number of pages	9
Journal	Journal of Vascular and Interventional Radiology
Volume	16
Issue number	2 I
DOIs	https://doi.org/10.1097/01.RVI.00001142592.89564.F9
State	Published - Feb 2005

Funding

DataMedix Corporation, Brookhaven, PA, served as the contract research organization for MDS Nordion, Ottawa, ON, Canada. R.S. has received consulting fees from MDS Nordion. This study was supported in part by MDS Nordion.

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Radiology Nuclear Medicine and imaging

Access to Document

10.1097/01.RVI.00001142592.89564.F9

Cite this

Goin, J. E., Salem, R., Carr, B. I., Dancey, J. E., Soulen, M. C., Geschwind, J. F. H., Goin, K., Van Buskirk, M., & Thurston, K. (2005). Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: Factors associated with liver toxicities. Journal of Vascular and Interventional Radiology, 16(2 I), 205-213. https://doi.org/10.1097/01.RVI.00001142592.89564.F9

@article{b1e03a6cddc64dc2b41cff3d695415cf,

title = "Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: Factors associated with liver toxicities",

abstract = "PURPOSE: Intraarterial injection of yttrium 90 microspheres (TheraSpheres) is used in the treatment of hepatocellular carcinoma (HCC). This article presents an analysis of the incidence of liver toxicities (liver-related events) and pretreatment factors associated with liver toxicities after TheraSphere treatment. PATIENTS AND METHODS: Eighty-eight TheraSphere-treated patients with low 90-day mortality risk were selected for analysis, with liver toxicities coded with use of standard oncology criteria. Descriptive and inferential statistical methods were applied to estimate the incidence of liver toxicities and to evaluate the influence of liver radiation dose and various pretreatment factors on the risk of their occurrence. RESULTS: Sixty-eight liver toxicities occurred in 37 of the 88 patients (42%). Thirty-two patients (36%) experienced 50 liver toxicities after the first treatment and nine of 23 patients (39%) who received a second treatment experienced 18 liver toxicities. Pretreatment total bilirubin and liver radiation dose were found to be associated with the risk of at least one liver toxicity and with the time to first occurrence of a liver toxicity after first treatment. Pretreatment total bilirubin also was associated with liver toxicities after the second treatment. Most of the toxicities resolved; however, those that did not resolve were attributed to tumor progression or advancing cirrhosis. CONCLUSIONS: The risk of liver toxicities in patients with unresectable HCC treated with TheraSpheres increases with increasing pretreatment total bilirubin level and liver radiation dose to a maximum of 150 Gy for a single administration. The toxicities attributed to treatment resolved over time, and none of the patients studied had confirmed radiation-induced liver disease. Consequently, doses as high as 150 Gy on a single administration and as high as 268 Gy on repeated administrations were well tolerated.",

author = "Goin, {James E.} and Riad Salem and Carr, {Brian I.} and Dancey, {Janet E.} and Soulen, {Michael C.} and Geschwind, {Jean Francois H.} and Kathleen Goin and {Van Buskirk}, Mark and Kenneth Thurston",

note = "Funding Information: DataMedix Corporation, Brookhaven, PA, served as the contract research organization for MDS Nordion, Ottawa, ON, Canada. R.S. has received consulting fees from MDS Nordion. This study was supported in part by MDS Nordion. Copyright: Copyright 2017 Elsevier B.V., All rights reserved.",

year = "2005",

month = feb,

doi = "10.1097/01.RVI.00001142592.89564.F9",

language = "English (US)",

volume = "16",

pages = "205--213",

journal = "Journal of Vascular and Interventional Radiology",

issn = "1051-0443",

publisher = "Elsevier Inc.",

number = "2 I",

}

Goin, JE, Salem, R, Carr, BI, Dancey, JE, Soulen, MC, Geschwind, JFH, Goin, K, Van Buskirk, M & Thurston, K 2005, 'Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: Factors associated with liver toxicities', Journal of Vascular and Interventional Radiology, vol. 16, no. 2 I, pp. 205-213. https://doi.org/10.1097/01.RVI.00001142592.89564.F9

TY - JOUR

T1 - Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres

T2 - Factors associated with liver toxicities

AU - Goin, James E.

AU - Salem, Riad

AU - Carr, Brian I.

AU - Dancey, Janet E.

AU - Soulen, Michael C.

AU - Geschwind, Jean Francois H.

AU - Goin, Kathleen

AU - Van Buskirk, Mark

AU - Thurston, Kenneth

N1 - Funding Information: DataMedix Corporation, Brookhaven, PA, served as the contract research organization for MDS Nordion, Ottawa, ON, Canada. R.S. has received consulting fees from MDS Nordion. This study was supported in part by MDS Nordion. Copyright: Copyright 2017 Elsevier B.V., All rights reserved.

PY - 2005/2

Y1 - 2005/2

N2 - PURPOSE: Intraarterial injection of yttrium 90 microspheres (TheraSpheres) is used in the treatment of hepatocellular carcinoma (HCC). This article presents an analysis of the incidence of liver toxicities (liver-related events) and pretreatment factors associated with liver toxicities after TheraSphere treatment. PATIENTS AND METHODS: Eighty-eight TheraSphere-treated patients with low 90-day mortality risk were selected for analysis, with liver toxicities coded with use of standard oncology criteria. Descriptive and inferential statistical methods were applied to estimate the incidence of liver toxicities and to evaluate the influence of liver radiation dose and various pretreatment factors on the risk of their occurrence. RESULTS: Sixty-eight liver toxicities occurred in 37 of the 88 patients (42%). Thirty-two patients (36%) experienced 50 liver toxicities after the first treatment and nine of 23 patients (39%) who received a second treatment experienced 18 liver toxicities. Pretreatment total bilirubin and liver radiation dose were found to be associated with the risk of at least one liver toxicity and with the time to first occurrence of a liver toxicity after first treatment. Pretreatment total bilirubin also was associated with liver toxicities after the second treatment. Most of the toxicities resolved; however, those that did not resolve were attributed to tumor progression or advancing cirrhosis. CONCLUSIONS: The risk of liver toxicities in patients with unresectable HCC treated with TheraSpheres increases with increasing pretreatment total bilirubin level and liver radiation dose to a maximum of 150 Gy for a single administration. The toxicities attributed to treatment resolved over time, and none of the patients studied had confirmed radiation-induced liver disease. Consequently, doses as high as 150 Gy on a single administration and as high as 268 Gy on repeated administrations were well tolerated.

AB - PURPOSE: Intraarterial injection of yttrium 90 microspheres (TheraSpheres) is used in the treatment of hepatocellular carcinoma (HCC). This article presents an analysis of the incidence of liver toxicities (liver-related events) and pretreatment factors associated with liver toxicities after TheraSphere treatment. PATIENTS AND METHODS: Eighty-eight TheraSphere-treated patients with low 90-day mortality risk were selected for analysis, with liver toxicities coded with use of standard oncology criteria. Descriptive and inferential statistical methods were applied to estimate the incidence of liver toxicities and to evaluate the influence of liver radiation dose and various pretreatment factors on the risk of their occurrence. RESULTS: Sixty-eight liver toxicities occurred in 37 of the 88 patients (42%). Thirty-two patients (36%) experienced 50 liver toxicities after the first treatment and nine of 23 patients (39%) who received a second treatment experienced 18 liver toxicities. Pretreatment total bilirubin and liver radiation dose were found to be associated with the risk of at least one liver toxicity and with the time to first occurrence of a liver toxicity after first treatment. Pretreatment total bilirubin also was associated with liver toxicities after the second treatment. Most of the toxicities resolved; however, those that did not resolve were attributed to tumor progression or advancing cirrhosis. CONCLUSIONS: The risk of liver toxicities in patients with unresectable HCC treated with TheraSpheres increases with increasing pretreatment total bilirubin level and liver radiation dose to a maximum of 150 Gy for a single administration. The toxicities attributed to treatment resolved over time, and none of the patients studied had confirmed radiation-induced liver disease. Consequently, doses as high as 150 Gy on a single administration and as high as 268 Gy on repeated administrations were well tolerated.

UR - http://www.scopus.com/inward/record.url?scp=14644403629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14644403629&partnerID=8YFLogxK

U2 - 10.1097/01.RVI.00001142592.89564.F9

DO - 10.1097/01.RVI.00001142592.89564.F9

M3 - Article

C2 - 15713921

AN - SCOPUS:14644403629

SN - 1051-0443

VL - 16

SP - 205

EP - 213

JO - Journal of Vascular and Interventional Radiology

JF - Journal of Vascular and Interventional Radiology

IS - 2 I

ER -

Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: Factors associated with liver toxicities

Abstract

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this